$49.20
▼ $-0.83
(-1.66%)
Vol 4.6M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$11.5B
ROE
-31.4%
Margin
-139.6%
D/E
0.61
Beta
1.32
52W
$22–$49
Wall Street Consensus
30 analysts · Apr 20260
Strong Buy
3
Buy
21
Hold
3
Sell
3
Strong Sell
10.0%
Buy Rating
Price Chart
Similar Stocks
NTRA
Natera Inc
$31.7B
BIIB
Biogen Inc
P/E 16.0
$25.8B
UTHR
United Therapeutics Corp
P/E 16.5
$21.0B
RVMD
Revolution Medicines Inc
$15.4B
INCY
Incyte Corp
P/E 16.3
$19.4B
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33.0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
Earnings
Beat rate: 100.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-2.70 | $-2.11 | +$0.59 |
| Sep 2025 | $-2.15 | $-0.51 | +$1.64 |
| Jun 2025 | $-3.03 | $-2.13 | +$0.90 |
| Mar 2025 | $-3.20 | $-2.52 | +$0.68 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -27.5% | -27.5% | -27.5% | -27.5% | -31.4% | -31.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -581.0% | -94.3% | -94.3% | -94.3% | -139.6% | -139.6% |
| Gross Margin | 43.0% | 68.3% | 68.3% | 68.3% | 63.5% | 63.5% |
| D/E Ratio | 0.63 | 0.63 | 0.63 | 0.63 | 0.61 | 0.61 |
| Current Ratio | 3.93 | 3.93 | 3.93 | 3.93 | 3.92 | 3.92 |
Key Ratios
ROA (TTM)
-24.4%
P/S (TTM)
5.16
P/B
1.5
EPS (TTM)
$-8.05
CF/Share
$-7.54
Rev Growth 3Y
-44.0%
52W High
$48.92
52W Low
$22.28
$22.28
52-Week Range
$48.92
How does MRNA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
MRNA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
5.2
▼
60%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.5
▼
40%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
MRNA profitability vs Biotechnology peers
ROE
-31.4%
▲
53%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-139.6%
▲
51%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
63.5%
▼
19%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-24.4%
▲
48%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
MRNA financial health vs Biotechnology peers
D/E ratio
0.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
3.9
▼
12%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
1.3
▲
36%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
MRNA fundamentals radar
MRNA
Peer median
Industry
MRNA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio